BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36837851)

  • 1. Muscle Pathology in Dystrophic Rats and Zebrafish Is Unresponsive to Taurine Treatment, Compared to the
    Terrill JR; Huchet C; Le Guiner C; Lafoux A; Caudal D; Tulangekar A; Bryson-Richardson RJ; Sztal TE; Grounds MD; Arthur PG
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
    Terrill JR; Boyatzis A; Grounds MD; Arthur PG
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2097-108. PubMed ID: 23892094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.
    Terrill JR; Duong MN; Turner R; Le Guiner C; Boyatzis A; Kettle AJ; Grounds MD; Arthur PG
    Redox Biol; 2016 Oct; 9():276-286. PubMed ID: 27611888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dystrophic Dmd
    Krishnan VS; Thanigaiarasu LP; White R; Crew R; Larcher T; Le Guiner C; Grounds MD
    Mol Cell Neurosci; 2020 Oct; 108():103549. PubMed ID: 32890728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation.
    Terrill JR; Grounds MD; Arthur PG
    PLoS Curr; 2016 Apr; 8():. PubMed ID: 27679740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
    Terrill JR; Grounds MD; Arthur PG
    Int J Biochem Cell Biol; 2015 Sep; 66():141-8. PubMed ID: 26239309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
    Butchart LC; Terrill JR; Rossetti G; White R; Filipovska A; Grounds MD
    Int J Biochem Cell Biol; 2018 Jun; 99():52-63. PubMed ID: 29578051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidised Albumin Levels in Plasma and Skeletal Muscle as Biomarkers of Disease Progression and Treatment Efficacy in Dystrophic
    Terrill JR; Bautista APR; Tsioutsias I; Grounds MD; Arthur PG
    Antioxidants (Basel); 2024 Jun; 13(6):. PubMed ID: 38929159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Blood Biomarker for Duchenne Muscular Dystrophy Shows That Oxidation State of Albumin Correlates with Protein Oxidation and Damage in Mdx Muscle.
    Al-Mshhdani BA; Grounds MD; Arthur PG; Terrill JR
    Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
    Barker RG; Wyckelsma VL; Xu H; Murphy RM
    Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The location of protein oxidation in dystrophic skeletal muscle from the mdx mouse model of Duchenne muscular dystrophy.
    Iwasaki T; Terrill JR; Kawarai K; Miyata Y; Tagami T; Maeda N; Hasegawa Y; Watanabe T; Grounds MD; Arthur PG
    Acta Histochem; 2022 Dec; 124(8):151959. PubMed ID: 36270048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of high dose taurine treatment in juvenile dystrophic mdx mice are offset by growth restriction.
    Terrill JR; Pinniger GJ; Nair KV; Grounds MD; Arthur PG
    PLoS One; 2017; 12(11):e0187317. PubMed ID: 29095865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the effect of taurine supplementation on muscle taurine content in the mdx mouse model of Duchenne muscular dystrophy using chemically specific synchrotron imaging.
    Terrill JR; Webb SM; Arthur PG; Hackett MJ
    Analyst; 2020 Nov; 145(22):7242-7251. PubMed ID: 32893271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy.
    Alves FM; Kysenius K; Caldow MK; Hardee JP; Chung JD; Trieu J; Hare DJ; Crouch PJ; Ayton S; Bush AI; Lynch GS; Koopman R
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1541-1553. PubMed ID: 35249268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
    Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
    Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
    Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
    Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular phenotype of the
    Szabó PL; Ebner J; Koenig X; Hamza O; Watzinger S; Trojanek S; Abraham D; Todt H; Kubista H; Schicker K; Remy S; Anegon I; Kiss A; Podesser BK; Hilber K
    Dis Model Mech; 2021 Feb; 14(2):. PubMed ID: 33619211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.